Dapivirine Ring: Phase III Results
Overview of results: Two large clinical trials — The Ring Study and ASPIRE — showed in 2016 that IPM's monthly vaginal ring containing the antiretroviral drug dapivirine can help reduce women's HIV-1 risk by approximately 30 percent overall and is safe for long-term use.
Greater HIV risk reduction associated with increased ring use: Participants who used the ring at least some of the time saw their HIV infection risk cut by 45 percent across both studies.
Next steps for the ring: IPM, the ring's developer, is pursuing approvals from global and national regulatory authorities to license the product in countries where women face the highest risk.
Two open-label extension studies, DREAM and HOPE, are providing the ring to former Ring Study and ASPIRE participants, respectively.
First-long-acting HIV prevention method: The dapivirine ring could be an important new self-initiated option for women, who bear the greatest burden of the global HIV/AIDS epidemic.
Impact: Modeling studies show that microbicides like the dapivirine ring would be cost-effective and have a significant public health impact as part of a broader toolkit that could avert tens of millions of HIV infections over time.
Learn more about the results from the Phase III dapivirine ring studies:
- IPM press release on new data analyses (July 2016): IPM’s dapivirine ring may offer significant HIV protection when used consistently, new data analyses suggest
- IPM press release on ring results (Feb. 2016): Two Large Studies Show IPM’s Monthly Vaginal Ring Helps Protect Women Against HIV
- MTN press release on ring results (Feb. 2016): Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase III trial
- IPM press release on additional analyses (July 2016): IPM’s dapivirine ring may offer significant HIV protection when used consistently, new data analyses suggest
- MTN press release on additional analyses (July 2016): Used consistently, monthly vaginal ring may be highly effective against HIV in women, suggest new analyses from ASPIRE
- Fact sheet: Sister Studies: The Ring Study and ASPIRE
- The Ring Study: CROI 2016 abstract and presentation
- ASPIRE: CROI 2016 abstract and presentation
- Fact sheet: IPM: Pioneering HIV prevention options for women